What the research found
Aging fat cells release a protein called asprosin into the bloodstream, which appears to damage the cells lining blood vessels by triggering mitochondrial dysfunction. When researchers studied this in mice and cell cultures, asprosin exposure caused mitochondrial membranes to break down, released mitochondrial DNA into the cell's cytoplasm, and activated an inflammatory pathway (cGAS-STING) linked to cellular aging. The cascade led to senescent endothelial cells and structural changes in blood vessels including wall thickening.
The team tested this by blocking asprosin with antibodies or using mice genetically unable to produce it. Both approaches reduced senescence markers and inflammatory signals in blood vessel cells, even when the mice were artificially aged. In isolated cell cultures, the effect was clear: conditioned media from fat cells that couldn't make asprosin was significantly less harmful to endothelial cells than media from normal fat cells.
Mechanistically, the damage traced back to mitochondrial reactive oxygen species (mtROS). Using a compound that specifically neutralises mtROS blunted asprosin's effects on senescence and cell survival, suggesting oxidative stress within mitochondria is central to the problem.
Why it matters for you
Asprosin levels appear to track with both aging and adipose tissue senescence—meaning this is one molecular link between body fat quality and vascular aging. If you're monitoring blood pressure or tracking inflammation biomarkers through MyKine, this represents one pathway through which excess or dysfunctional fat tissue accelerates endothelial dysfunction independent of BMI alone.
The mitochondrial angle is particularly relevant if you're using protocols aimed at mitochondrial health (antioxidant supplementation, exercise training, or metabolic optimisation). mtROS reduction blunted asprosin's effects in these experiments, which aligns with the rationale behind compounds like mitoQ or focused aerobic training for vascular health. If fat mass is rising despite stable weight, or if you're seeing inflammatory creep despite protocol adherence, asprosin elevation in adipose tissue could be a contributing factor worth considering alongside insulin sensitivity and lipid profiles.
This also contextualises why senolytic or senolytics strategies might matter beyond just circulating senescent cells—the cells secreting harmful molecules (here, aging adipocytes) are relevant targets, not just their downstream effects on vessels.
Caveats
- Animal-heavy: Primary evidence from mice (some artificially aged with D-galactose, an artificial senescence model). Human validation of asprosin's role in vascular aging remains limited.
- In vitro mechanisms: The mitochondrial pathway was established mostly in cultured endothelial cells, not intact vessels or tissues.
- No direct clinical intervention yet: The researchers explicitly note uncertainty about whether blocking asprosin would outperform current vascular treatments—this is mechanistic insight, not yet a therapeutic proposal.
- Incomplete mechanism: Authors acknowledge they haven't fully mapped what drives asprosin overproduction during aging or how it relates to upstream senescence drivers.
- No biomarker accessibility: Asprosin is not yet a routine clinical or app-trackable measure; practical utility depends on future assay development and validation.